XNAS 30 Apr, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.99 per share. | 17 Apr 2026 | 20,225 | 246,426 | - | 40.0 | 808,844 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.08 per share. | 10 Apr 2026 | 10,200 | 266,651 | - | 35.1 | 357,797 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.97 per share. | 10 Apr 2026 | 9,165 | 276,851 | - | 35.0 | 320,537 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.98 per share. | 10 Apr 2026 | 500 | 286,016 | - | 35.0 | 17,490 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 08 Apr 2026 | 360 | 286,516 | - | 34.9 | 12,564 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.55 per share. | 30 Mar 2026 | 2,839 | 159,914 | - | 28.6 | 81,062 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.04 per share. | 30 Mar 2026 | 7,161 | 162,753 | - | 28.0 | 200,795 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.99 per share. | 25 Mar 2026 | 10,115 | 286,876 | - | 30.0 | 303,355 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.93 per share. | 05 Mar 2026 | 2,014 | 169,914 | - | 28.9 | 58,265 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.05 per share. | 18 Feb 2026 | 3,552 | 558,528 | - | 29.1 | 103,191 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.80 per share. | 18 Feb 2026 | 2,100 | 20,729 | - | 29.8 | 62,573 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.04 per share. | 18 Feb 2026 | 2,983 | 22,829 | - | 29.0 | 86,639 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.80 per share. | 18 Feb 2026 | 2,281 | 556,247 | - | 29.8 | 67,970 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 17 Feb 2026 | 900 | 394,675 | - | 28.0 | 25,219 | Common Stock |
| David Bredt | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 6,000 | 88,080 | - | - | Stock Options (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 17 Feb 2026 | 6,000 | 393,075 | - | 1.8 | 10,800 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.59 per share. | 17 Feb 2026 | 2,200 | 387,075 | - | 29.6 | 65,108 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.95 per share. | 17 Feb 2026 | 5,400 | 389,275 | - | 28.9 | 156,328 | Common Stock |
| Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 148,000 | 148,000 | - | - | Stock Option (Right to Buy) | |
| Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 428,000 | 428,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey Sevigny | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 132,000 | 132,000 | - | - | Stock Option (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 103,000 | 103,000 | - | - | Stock Option (Right to Buy) | |
| Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.12 per share. | 20 Jan 2026 | 5,833 | 562,080 | - | 26.1 | 152,333 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.11 per share. | 20 Jan 2026 | 5,083 | 25,812 | - | 26.1 | 132,737 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 15 Jan 2026 | 8,300 | 395,775 | - | 26.8 | 222,652 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 15 Jan 2026 | 200 | 395,575 | - | 27.4 | 5,480 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 31 Dec 2025 | 6,567 | 404,075 | - | 30.0 | 197,338 | Common Stock |
| David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 18,000 | 410,642 | - | - | Common Stock | |
| Swamy Yeleswaram | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 31 Dec 2025 | 2,840 | 296,991 | - | 30.1 | 85,342 | Common Stock |
| Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 9,000 | 299,831 | - | - | Common Stock | |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.84 per share. | 17 Dec 2025 | 2,441 | 571,305 | - | 28.8 | 70,393 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 17 Dec 2025 | 515 | 30,895 | - | 31.0 | 15,985 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 17 Dec 2025 | 2,421 | 31,410 | - | 30.0 | 72,722 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.84 per share. | 17 Dec 2025 | 2,147 | 33,831 | - | 28.8 | 61,925 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.04 per share. | 17 Dec 2025 | 600 | 567,913 | - | 31.0 | 18,622 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 17 Dec 2025 | 2,792 | 568,513 | - | 30.0 | 83,862 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.68 per share. | 15 Dec 2025 | 796 | 392,642 | - | 30.7 | 24,419 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.95 per share. | 15 Dec 2025 | 7,704 | 393,438 | - | 29.9 | 230,711 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 26 Nov 2025 | 5,000 | 176,928 | - | 1.8 | 9,000 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2025 | 5,000 | 105,407 | - | - | Stock Option (Right to Buy) | |
| Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.10 per share. | 26 Nov 2025 | 5,000 | 171,928 | - | 30.1 | 150,487 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.91 per share. | 17 Nov 2025 | 2,242 | 38,819 | - | 24.9 | 55,850 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.43 per share. | 17 Nov 2025 | 3,056 | 573,746 | - | 25.4 | 77,715 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.92 per share. | 17 Nov 2025 | 2,777 | 576,802 | - | 24.9 | 69,216 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.44 per share. | 17 Nov 2025 | 2,841 | 35,978 | - | 25.4 | 72,267 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.39 per share. | 17 Nov 2025 | 5,344 | 401,142 | - | 25.4 | 135,696 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.84 per share. | 17 Nov 2025 | 3,156 | 406,486 | - | 24.8 | 78,395 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.75 per share. | 15 Oct 2025 | 4,328 | 41,816 | - | 25.7 | 111,429 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 15 Oct 2025 | 755 | 41,061 | - | 26.2 | 19,760 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.14 per share. | 15 Oct 2025 | 1,186 | 579,579 | - | 26.1 | 31,001 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.72 per share. | 15 Oct 2025 | 4,647 | 580,765 | - | 25.7 | 119,539 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.73 per share. | 15 Oct 2025 | 7,418 | 410,724 | - | 25.7 | 190,887 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.16 per share. | 15 Oct 2025 | 1,082 | 409,642 | - | 26.2 | 28,310 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 17 Sep 2025 | 34,885 | 46,844 | - | 26.3 | 917,542 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.04 per share. | 17 Sep 2025 | 700 | 46,144 | - | 27.0 | 18,930 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 17 Sep 2025 | 1,400 | 585,412 | - | 26.9 | 37,624 | Common Stock |
| Abraham N. Ceesay | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.30 per share. | 17 Sep 2025 | 39,435 | 586,812 | - | 26.3 | 1,037,101 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.66 per share. | 15 Sep 2025 | 3,402 | 418,142 | - | 24.7 | 83,888 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 15 Sep 2025 | 5,098 | 421,544 | - | 23.9 | 121,761 | Common Stock |
| Steven M. Paul | Director | Purchase of securities on an exchange or from another person at price $ 24.50 per share. | 12 Sep 2025 | 28,284 | 28,284 | - | 24.5 | 692,947 | Common Stock |
| Steven M. Paul | Director | Purchase of securities on an exchange or from another person at price $ 24.97 per share. | 12 Sep 2025 | 13,382 | 41,666 | - | 25.0 | 334,165 | Common Stock |
| Reid M. Huber | Director | Purchase of securities on an exchange or from another person at price $ 24.48 per share. | 12 Sep 2025 | 20,400 | 20,400 | - | 24.5 | 499,374 | Common Stock |
| Wendy B. Young | Director | Purchase of securities on an exchange or from another person at price $ 22.60 per share. | 11 Sep 2025 | 3,500 | 9,500 | - | 22.6 | 79,100 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2025 | 5,000 | 110,407 | - | - | Stock Option (Right to Buy) | |
| Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.33 per share. | 08 Sep 2025 | 5,000 | 171,928 | - | 38.3 | 191,650 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 08 Sep 2025 | 5,000 | 176,928 | - | 1.8 | 9,000 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.79 per share. | 15 Aug 2025 | 200 | 426,642 | - | 15.8 | 3,158 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.98 per share. | 15 Aug 2025 | 8,300 | 426,842 | - | 15.0 | 124,308 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 15 Jul 2025 | 8,500 | 435,142 | - | 14.0 | 118,962 | Common Stock |
| John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Robert J. Perez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| James I. Healy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| Reid M. Huber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Ramiro Sanchez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| Wendy B. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 16 Jun 2025 | 8,500 | 443,642 | - | 11.0 | 93,522 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.56 per share. | 15 May 2025 | 8,500 | 452,142 | - | 9.6 | 81,262 | Common Stock |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.57 per share. | 15 Apr 2025 | 8,500 | 460,642 | - | 9.6 | 81,310 | Common Stock |
| Jeffrey Sevigny | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 14 Mar 2025 | 8,500 | 469,142 | - | 10.8 | 92,205 | Common Stock |
| Troy A. Ignelzi | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.98 per share. | 12 Mar 2025 | 100 | 10,000 | - | 10.0 | 998 | Common Stock |
| Troy A. Ignelzi | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 10.10 per share. | 12 Mar 2025 | 9,900 | 9,900 | - | 10.1 | 99,990 | Common Stock |
| Wendy B. Young | Director | Purchase of securities on an exchange or from another person at price $ 10.21 per share. | 12 Mar 2025 | 6,000 | 6,000 | - | 10.2 | 61,250 | Common Stock |
| Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 13,987 | 171,928 | - | 0 | Common Stock | |
| Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 142,000 | 142,000 | - | - | Stock Option (Right to Buy) | |
| Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 428,000 | 428,000 | - | - | Stock Option (Right to Buy) | |
| Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 129,000 | 129,000 | - | - | Stock Option (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Wendy B. Young | Director | 07 Nov 2024 | 29,756 | 29,756 | - | - | Stock Option (Right to Buy) | ||
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,661 | 38,226 | - | 25.0 | 116,598 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,657 | 33,565 | - | 24.2 | 88,543 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,544 | 37,102 | - | 25.0 | 113,671 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,565 | 32,558 | - | 24.2 | 86,316 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,538 | 28,993 | - | 23.1 | 81,641 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.06 per share. | 01 Jul 2024 | 2,559 | 39,661 | - | 26.1 | 66,675 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,799 | 21,660 | - | 23.1 | 87,664 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 24.21 per share. | 01 Jul 2024 | 3,828 | 25,488 | - | 24.2 | 92,684 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 25.02 per share. | 01 Jul 2024 | 4,878 | 30,366 | - | 25.0 | 122,026 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.05 per share. | 01 Jul 2024 | 2,748 | 33,114 | - | 26.1 | 71,599 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 23.08 per share. | 01 Jul 2024 | 3,630 | 29,908 | - | 23.1 | 83,764 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 26.06 per share. | 01 Jul 2024 | 2,625 | 40,851 | - | 26.1 | 68,395 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 17,861 | 17,861 | - | 17 | 303,637 | Common Stock |
| James I. Healy | Director | 10 Jun 2024 | 1,392,738 | 1,392,738 | - | 0 | Common Stock | ||
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 470,589 | 1,863,327 | - | 17 | 8,000,013 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 18,641 | 18,641 | - | 17 | 316,897 | Common Stock |
| James I. Healy | Director | 10 Jun 2024 | 11,924,138 | 0 | - | - | Series B Preferred Stock | ||
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 25,455 | 25,455 | - | 17 | 432,735 | Common Stock |
| James I. Healy | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 10 Jun 2024 | 26,278 | 26,278 | - | 17 | 446,726 | Common Stock |
| Bradley S. Galer | Chief Medical Officer | 06 Jun 2024 | 123,818 | 123,818 | - | - | Stock Option (Right to Buy) | ||
| Troy A. Ignelzi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 81,366 | 81,366 | - | - | Stock Option (Right to Buy) | |
| Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 530,647 | 530,647 | - | - | Stock Option (Right to Buy) | |
| Cheryl Gault | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 88,442 | 88,442 | - | - | Stock Option (Right to Buy) | |
| David Bredt | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 28,302 | 28,302 | - | - | Stock Option (Right to Buy) | |
| Swamy Yeleswaram | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 84,904 | 84,904 | - | - | Stock Option (Right to Buy) |